Skip to main content
Premium Trial:

Request an Annual Quote

454, WashU Pen Sequencing, Gene-Expression Alliance

NEW YORK, Dec. 7 (GenomeWeb News) - 454 Life Sciences and the Genome Sequencing Center at the Washington University School of Medicine plan to sequence disease-causing pathogens and study expression profiles of genes in mammalian cells and tissues, the partners said today.

 

The first part of the plan calls for GSC and 454 scientists to sequence and analyze the genomes of disease-causing pathogens using 454's Genome Sequencer 20 System. During the second part of the plan, scientists from the two partners will sequence RNA to assess the expression profiles of genes in mammalian cells and tissues.

 

Christopher McLeod, 454's president and CEO, noted that the cooperation "could be expanded to incorporate additional research topics in the future."

 

Financial details were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.